This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Johnson, T. R.
Right arrow Articles by Graham, B. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Johnson, T. R.
Right arrow Articles by Graham, B. S.

 Previous Article  |  Next Article 

Journal of Virology, June 2004, p. 6024-6032, Vol. 78, No. 11
0022-538X/04/$08.00+0     DOI: 10.1128/JVI.78.11.6024-6032.2004

Respiratory Syncytial Virus (RSV) G Glycoprotein Is Not Necessary for Vaccine-Enhanced Disease Induced by Immunization with Formalin-Inactivated RSV

Teresa R. Johnson,1* Michael N. Teng,2,{dagger} Peter L. Collins,2 and Barney S. Graham1

Viral Pathogenesis Laboratory, Vaccine Research Center,1 Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 208922

Received 4 October 2003/ Accepted 9 February 2004

Following respiratory syncytial virus (RSV) challenge, mice immunized with RSV G or with formalin-inactivated RSV (FI-RSV) exhibit severe disease associated with type 2 cytokine production and pulmonary eosinophilia. This has led to the proposal that the presence of RSV G is the factor in FI-RSV that induces disease-enhancing T-cell responses. Therefore, we evaluated the role of RSV G and its immunodominant region in the induction of aberrant immune responses during FI-RSV immunization. BALB/c mice were immunized with FI preparations of wild-type (wt) RSV or recombinant RSV (rRSV) containing deletions of (i) the entire G gene, (ii) the region of the G gene encoding amino acids 187 to 197 of the immunodominant region, or (iii) the entire SH gene. After challenge, illness, RSV titers, cytokine levels, and pulmonary eosinophilia were measured. Peak RSV titers postchallenge were significantly greater in mice immunized with FI preparations of the deletion viruses than in those immunized with FI-rRSV wt, suggesting that the absence of G or SH in FI-RSV reduced its protective efficacy. Deletion of G or its epitope did not reduce illness, cytokine production, or eosinophilia relative to that in mice immunized with FI-rRSV wt. While cytokine levels and eosinophilia were similar, illness was reduced in mice immunized with SH-deleted FI-RSV. These data suggest that G-specific immune responses may be important for vaccine-induced protection and are not solely the basis for FI-RSV vaccine-enhanced illness. These data suggest that the method of RSV antigen delivery, rather than the protein composition, influences the phenotype of the induced immune responses and that RSV G should not necessarily be excluded from potential vaccine strategies.

* Corresponding author. Mailing address: VRC, NIAID, NIH, Bldg. 40 Room 2614, 40 Convent Dr., MSC 3017, Bethesda, MD 20892-3017. Phone: (301) 594-8570. Fax: (301) 480-2771. E-mail: teresaj{at}nih.gov.

{dagger} Present address: Department of Biochemistry and Molecular Biology, Pennsylvania State University, University Park, PA 16802.

Journal of Virology, June 2004, p. 6024-6032, Vol. 78, No. 11
0022-538X/04/$08.00+0     DOI: 10.1128/JVI.78.11.6024-6032.2004




This article has been cited by other articles:

  • Percopo, C. M., Qiu, Z., Phipps, S., Foster, P. S., Domachowske, J. B., Rosenberg, H. F. (2009). Pulmonary Eosinophils and Their Role in Immunopathologic Responses to Formalin-Inactivated Pneumonia Virus of Mice. J. Immunol. 183: 604-612 [Abstract] [Full Text]  
  • Olson, M. R., Varga, S. M. (2009). Fas Ligand Is Required for the Development of Respiratory Syncytial Virus Vaccine-Enhanced Disease. J. Immunol. 182: 3024-3031 [Abstract] [Full Text]  
  • Olson, M. R., Hartwig, S. M., Varga, S. M. (2008). The Number of Respiratory Syncytial Virus (RSV)-Specific Memory CD8 T Cells in the Lung Is Critical for Their Ability to Inhibit RSV Vaccine-Enhanced Pulmonary Eosinophilia. J. Immunol. 181: 7958-7968 [Abstract] [Full Text]  
  • Collins, P. L., Graham, B. S. (2008). Viral and Host Factors in Human Respiratory Syncytial Virus Pathogenesis. J. Virol. 82: 2040-2055 [Full Text]  
  • Yu, J.-R., Kim, S., Lee, J.-B., Chang, J. (2008). Single Intranasal Immunization with Recombinant Adenovirus-Based Vaccine Induces Protective Immunity against Respiratory Syncytial Virus Infection. J. Virol. 82: 2350-2357 [Abstract] [Full Text]  
  • Castilow, E. M., Meyerholz, D. K., Varga, S. M. (2008). IL-13 Is Required for Eosinophil Entry into the Lung during Respiratory Syncytial Virus Vaccine-Enhanced Disease. J. Immunol. 180: 2376-2384 [Abstract] [Full Text]  
  • Hamelin, M.-E., Couture, C., Sackett, M. K., Boivin, G. (2007). Enhanced lung disease and Th2 response following human metapneumovirus infection in mice immunized with the inactivated virus. J. Gen. Virol. 88: 3391-3400 [Abstract] [Full Text]  
  • Olson, M. R., Varga, S. M. (2007). CD8 T Cells Inhibit Respiratory Syncytial Virus (RSV) Vaccine-Enhanced Disease. J. Immunol. 179: 5415-5424 [Abstract] [Full Text]  
  • Naylor, C. J., Ling, R., Edworthy, N., Savage, C. E., Easton, A. J. (2007). Avian metapneumovirus SH gene end and G protein mutations influence the level of protection of live-vaccine candidates. J. Gen. Virol. 88: 1767-1775 [Abstract] [Full Text]  
  • Melendi, G. A., Hoffman, S. J., Karron, R. A., Irusta, P. M., Laham, F. R., Humbles, A., Schofield, B., Pan, C.-H., Rabold, R., Thumar, B., Thumar, A., Gerard, N. P., Mitzner, W., Barnum, S. R., Gerard, C., Kleeberger, S. R., Polack, F. P. (2007). C5 Modulates Airway Hyperreactivity and Pulmonary Eosinophilia during Enhanced Respiratory Syncytial Virus Disease by Decreasing C3a Receptor Expression. J. Virol. 81: 991-999 [Abstract] [Full Text]  
  • Openshaw, P. J. M. (2005). Antiviral Immune Responses and Lung Inflammation after Respiratory Syncytial Virus Infection. Proc Am Thorac Soc 2: 121-125 [Abstract] [Full Text]  
  • Hamelin, M.-E., Yim, K., Kuhn, K. H., Cragin, R. P., Boukhvalova, M., Blanco, J. C. G., Prince, G. A., Boivin, G. (2005). Pathogenesis of Human Metapneumovirus Lung Infection in BALB/c Mice and Cotton Rats. J. Virol. 79: 8894-8903 [Abstract] [Full Text]  
  • Openshaw, P. J. M., Tregoning, J. S. (2005). Immune Responses and Disease Enhancement during Respiratory Syncytial Virus Infection. Clin. Microbiol. Rev. 18: 541-555 [Abstract] [Full Text]  
  • Polack, F. P., Irusta, P. M., Hoffman, S. J., Schiatti, M. P., Melendi, G. A., Delgado, M. F., Laham, F. R., Thumar, B., Hendry, R. M., Melero, J. A., Karron, R. A., Collins, P. L., Kleeberger, S. R. (2005). The cysteine-rich region of respiratory syncytial virus attachment protein inhibits innate immunity elicited by the virus and endotoxin. Proc. Natl. Acad. Sci. USA 102: 8996-9001 [Abstract] [Full Text]  
  • Huang, Y., Anderson, R. (2005). Modulation of Protective Immunity, Eosinophilia, and Cytokine Responses by Selective Mutagenesis of a Recombinant G Protein Vaccine against Respiratory Syncytial Virus. J. Virol. 79: 4527-4532 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»